JP2007538009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007538009A5 JP2007538009A5 JP2007511527A JP2007511527A JP2007538009A5 JP 2007538009 A5 JP2007538009 A5 JP 2007538009A5 JP 2007511527 A JP2007511527 A JP 2007511527A JP 2007511527 A JP2007511527 A JP 2007511527A JP 2007538009 A5 JP2007538009 A5 JP 2007538009A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- phospholipase
- membered ring
- inhibitor
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000015439 Phospholipases Human genes 0.000 claims 21
- 108010064785 Phospholipases Proteins 0.000 claims 21
- 239000003112 inhibitor Substances 0.000 claims 16
- 230000002401 inhibitory effect Effects 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 230000001419 dependent Effects 0.000 claims 11
- 125000002837 carbocyclic group Chemical group 0.000 claims 10
- 239000002253 acid Chemical group 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 125000003277 amino group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000004442 acylamino group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Chemical class 0.000 claims 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 239000011593 sulfur Substances 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- ROPVXAWEVYWEQY-UHFFFAOYSA-N 1,1,1,2,2-pentafluoro-7-phenylheptan-3-one Chemical compound FC(F)(F)C(F)(F)C(=O)CCCCC1=CC=CC=C1 ROPVXAWEVYWEQY-UHFFFAOYSA-N 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 230000001079 digestive Effects 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 210000000056 organs Anatomy 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 3
- 206010022489 Insulin resistance Diseases 0.000 claims 3
- 150000002894 organic compounds Chemical class 0.000 claims 3
- 239000003428 phospholipase inhibitor Substances 0.000 claims 3
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 239000011574 phosphorus Substances 0.000 claims 3
- 229940107161 Cholesterol Drugs 0.000 claims 2
- 208000009576 Hypercholesterolemia Diseases 0.000 claims 2
- 208000006575 Hypertriglyceridemia Diseases 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004634 feeding behavior Effects 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 125000005842 heteroatoms Chemical group 0.000 claims 2
- -1 indole compound Chemical class 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 229940040461 Lipase Drugs 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 102000011720 Lysophospholipase Human genes 0.000 claims 1
- 108020002496 Lysophospholipase Proteins 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 230000036091 Metabolic activity Effects 0.000 claims 1
- 230000036740 Metabolism Effects 0.000 claims 1
- 229940067631 Phospholipids Drugs 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 230000001925 catabolic Effects 0.000 claims 1
- 235000021271 drinking Nutrition 0.000 claims 1
- 230000035622 drinking Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 102000004882 lipase Human genes 0.000 claims 1
- 108090001060 lipase Proteins 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 230000002503 metabolic Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000035786 metabolism Effects 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 0 *C1C(*)C2C(*)C(*)C(*)C(*)C2C1* Chemical compound *C1C(*)C2C(*)C(*)C(*)C(*)C2C1* 0.000 description 1
Claims (38)
- 被験者の脂肪やグルコース、コレステロールの代謝を調節するための製剤として使用する薬剤の製造のための、ホスホリパーゼ-A2 IB阻害薬の使用であって、ここでこのホスホリパーゼ-A2 IB阻害薬は、五員環と六員環を融合した部分を有する置換有機化合物またはその塩を含む、使用。
- 被験者の疾患 (体重関連疾患、インスリン関連疾患、コレステロール関連疾患、およびこれらの組合せから選択される)を治療するための製剤として使用する薬剤の製造のための、ホスホリパーゼA 2 IB阻害薬の使用であって、ホスホリパーゼA2IB阻害薬は五員環と六員環を融合した部分を有する置換有機化合物またはその塩から成る、使用。
- 食べられる食品とホスホリパーゼ-A2 IB阻害薬とを含む食品組成で、このホスホリパーゼA2 IB阻害薬は、五員環と六員環を融合した部分を有する置換有機化合物またはその塩から成る。
- 疾患が、肥満、糖尿病、インスリン抵抗性、グルコース不耐性、高コレステロール血症、高トリグリセリド血症、およびこれらの組合せのうちいずれかである場合の、請求項2の発明。
- ホスホリパーゼ-A2 IB阻害薬が、1つまたは複数のヘテロ原子を含む五員環と六員環を融合したもので、このヘテロ原子は、この五員環または六員環の環構造内、または五員環と六員環それぞれの環構造内にある、請求項1〜4のいずれかの発明。
- R1〜R7のうち独立して選択される2つの隣り合う置換基間に別の環をもつことができ、この追加環は五員環、六員環、七員環のいずれかを独立に選び、また炭素環、複素環、あるいはこの組合せにすることができる、請求項6の発明。
- ホスホリパーゼA2 IB阻害薬が、インドール化合物、またはその塩から成る、請求項1〜5のいずれかの発明。
- それぞれの化学式について、R1 〜R7 のうち独立して選択される2つの隣り合う置換基間に別の環をもつことができ、この追加環は五員環、六員環、七員環のいずれかを独立に選び、また炭素環、複素環、あるいはこの組合せにすることができる、請求項9の発明。
- 次の条件を満たす、請求項6、7、9、または10のいずれかの発明:
R1 は水素、酸素、イオウ、アミン基、ハロゲン基、水酸基 (−OH)、チオール基(−SH)、カルボニル基、酸基、アルキル基、アルケニル基、炭素環基、複素環基、置換された置換基の中から選択される;
R2 は水素、酸素、ハロゲン基、カルボニル基、アルキル基、アルケニル基、炭素環基、置換された置換基の中から選択される;
R3 は水素、酸素、イオウ、アミン基、水酸基 (−OH)、チオール基(−SH)、カルボニル基、酸基、アルキル基、複素環基、アシルアミノ基、オキシミル基、ヒドラジル基、置換された置換基の中から選択される;
R4 とR5はそれぞれ独立に、水素、酸素、イオウ、リン、アミン基、水酸基(−OH)、チオール基(−SH)、カルボニル基、酸基、アルキル基、アルケニル基、複素環基、アシルアミノ基、オキシミル基、ヒドラジル基、置換された置換基の中から選択される;
R6 は水素、酸素、アミン基、ハロゲン基、水酸基 (−OH)、酸基、アルキル基、炭素環基、アシルアミノ基、置換された置換基の中から選択される;
R7 は水素、ハロゲン基、チオール基 (−SH)、カルボニル基、酸基、アルキル基、アルケニル基、炭素環基、置換された置換基の中から選択される。 - R1がアルキル基、炭素環基、置換された置換基のいずれかである、請求項6、7、9〜11のいずれかの発明。
- R2がハロゲン基、アルキル基、置換された置換基のいずれかである、請求項6、7、9〜12のいずれかの発明。
- R3がカルボニル基、アシルアミノ基、オキシミル基、ヒドラジル基、置換された置換基のいずれかである、請求項6、7、9〜13のいずれかの発明。
- R4とR5がそれぞれ独立に、酸素、水酸基 (−OH)、酸基、アルキル基、置換された置換基のいずれかである、請求項6、7、9〜14のいずれかの発明。
- R6がアミン基、酸基、アルキル基、置換された置換基のいずれかである、請求項6、7、9〜15のいずれかの発明。
- R7が炭素環基、置換された置換基のいずれかである、請求項6、7、9〜16のいずれかの発明。
- ホスホリパーゼA2 IB阻害薬が、投与後または飲食後に、消化器官管腔内に集中して留まる、前述の請求項のいずれかの発明。
- ホスホリパーゼA2 IB阻害薬が、消化器官管腔内にある分泌ホスホリパーゼA2 IBのカルシウム依存性の活性を阻害する、前述の請求項のいずれかの発明。
- ホスホリパーゼA2 IB阻害薬が、膵臓分泌ホスホリパーゼA2 IBの活性を阻害する、前述の請求項のいずれかの発明。
- 疾患が肥満である場合の、請求項2およびそれに従属する請求項のいずれかの発明。
- 疾患がインスリン抵抗性である場合の、請求項2およびそれに従属する請求項のいずれかの発明。
- 疾患がグルコース不耐性である場合の、請求項2およびそれに従属する請求項のいずれかの発明。
- 疾患が高コレステロール血症である場合の、請求項2およびそれに従属する請求項のいずれかの発明。
- 疾患が高トリグリセリド血症である場合の、請求項2およびそれに従属する請求項のいずれかの発明。
- 疾患が2型糖尿病である場合の、請求項2およびそれに従属する請求項のいずれかの発明。
- 疾患が、肥満、インスリン抵抗性、グルコース不耐性のうち2つ以上である場合の、請求項2およびそれに従属する請求項のいずれかの発明。
- 疾患が肥満と2型糖尿病である場合の、請求項2およびそれに従属する請求項のいずれかの発明。
- 疾患が代謝症候群である場合の、請求項2およびそれに従属する請求項のいずれかの発明。
- ホスホリパーゼA2 IB阻害薬が経口投与される場合の、請求項1、2およびそれらに従属する請求項のいずれかの発明。
- ホスホリパーゼA2 IB阻害薬の効果的な用量が、ホスホリパーゼA2 IB活性の少なくとも約30%を阻害するのに足る、前述の請求項のいずれかの発明。
- 被験動物がヒトである、前述の請求項のいずれかの発明。
- ホスホリパーゼA2阻害薬が、リパーゼを基本的に阻害しない、前述の請求項のいずれかの発明。
- ホスホリパーゼA2阻害薬が、ホスホリパーゼBを基本的に阻害しない、前述の請求項のいずれかの発明。
- ホスホリパーゼ阻害薬が、ホスホリパーゼA2 の活性を阻害するけれども、リン脂質の代謝活性を有する他の消化器官ホスホリパーゼは基本的に阻害しない、前述の請求項のいずれかの発明。
- ホスホリパーゼ阻害薬が、ホスホリパーゼA2 の活性を阻害するけれども、ホスファチジルコリンまたはホスファチジルエタノールアミンの異化活性を有する他の消化器官ホスホリパーゼは基本的に阻害しない、前述の請求項のいずれかの発明。
- ホスホリパーゼ阻害薬が、ホスホリパーゼA2 の活性を阻害するけれども、消化器官粘膜細胞に結合した他のホスホリパーゼは基本的に阻害しない、前述の請求項のいずれかの発明。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/838,879 US20050244367A1 (en) | 2004-05-03 | 2004-05-03 | Phospholipase inhibitors localized in the gastrointestinal lumen |
PCT/US2005/015416 WO2005112646A2 (en) | 2004-05-03 | 2005-05-03 | Treatment of diet-related conditions using phospholipase-a2 inhibitors comprising indoles and related compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007538009A JP2007538009A (ja) | 2007-12-27 |
JP2007538009A5 true JP2007538009A5 (ja) | 2008-06-19 |
Family
ID=35187321
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007511528A Pending JP2007536249A (ja) | 2004-05-03 | 2005-05-03 | 消化器官管腔集中性ホスホリパーゼ阻害薬 |
JP2007511494A Pending JP2007536243A (ja) | 2004-05-03 | 2005-05-03 | ホスホリパーゼ−a2阻害薬を用いた、高コレステロール血症、高トリグリセリド血症、心臓血管疾患の治療 |
JP2007511527A Pending JP2007538009A (ja) | 2004-05-03 | 2005-05-03 | インドールおよび関連化合物から成るホスホリパーゼ−a2阻害薬を用いた、食事関連疾患の治療 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007511528A Pending JP2007536249A (ja) | 2004-05-03 | 2005-05-03 | 消化器官管腔集中性ホスホリパーゼ阻害薬 |
JP2007511494A Pending JP2007536243A (ja) | 2004-05-03 | 2005-05-03 | ホスホリパーゼ−a2阻害薬を用いた、高コレステロール血症、高トリグリセリド血症、心臓血管疾患の治療 |
Country Status (5)
Country | Link |
---|---|
US (3) | US20050244367A1 (ja) |
EP (3) | EP1747003A4 (ja) |
JP (3) | JP2007536249A (ja) |
CA (3) | CA2565416A1 (ja) |
WO (3) | WO2005112646A2 (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056279A2 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors |
WO2007056281A2 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors |
AU2007313706A1 (en) * | 2006-10-31 | 2008-05-08 | Wyeth | Liquid formulations of phospholipase enzyme inhibitors |
WO2008055148A2 (en) * | 2006-10-31 | 2008-05-08 | Wyeth | Semi-solid formulations of phospholipase enzyme inhibitors |
WO2009082491A1 (en) * | 2007-12-26 | 2009-07-02 | Alp Life Sciences, Llc | Nanovesontm: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases |
US20090197955A1 (en) * | 2008-01-31 | 2009-08-06 | Monsanto Company | Methods of improving dha deposition and related function and/or development |
EP2334295B1 (en) | 2008-09-02 | 2017-06-28 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
CN103819403B (zh) | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法 |
HUE051916T2 (hu) | 2009-04-29 | 2021-04-28 | Amarin Pharmaceuticals Ie Ltd | Stabil gyógyászati készítmény és annak alkalmazási módszerei |
NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
SG177254A1 (en) | 2009-06-15 | 2012-02-28 | Ian Osterloh | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
AU2013282394B2 (en) | 2012-06-29 | 2018-04-26 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
AU2013304812B2 (en) | 2012-08-21 | 2016-06-09 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
KR20230132619A (ko) | 2013-04-12 | 2023-09-15 | 알데릭스, 인코포레이티드 | Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법 |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
CN107684550B (zh) * | 2016-08-03 | 2020-04-10 | 徐天宏 | 糖尿病治疗产品及其制备与应用 |
AU2018205400B2 (en) | 2017-01-09 | 2022-07-14 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
EP3565811A1 (en) | 2017-01-09 | 2019-11-13 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
BR112020002322A2 (pt) | 2017-08-04 | 2020-09-01 | Ardelyx, Inc. | derivados de ácido glicirretinínico para o tratamento de hipercalemia |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
KR102296068B1 (ko) | 2018-09-24 | 2021-09-02 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
AU2020218255A1 (en) | 2019-02-07 | 2021-09-09 | Ardelyx, Inc. | Glycyrrhetinic acid derivatives for use in treating hyperkalemia |
WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7017227A (ja) * | 1969-12-27 | 1971-06-29 | ||
US4211765A (en) * | 1971-10-12 | 1980-07-08 | Monsanto Company | Method for controlling obesity |
US4432968A (en) * | 1980-10-20 | 1984-02-21 | The Dow Chemical Company | Weight control with fat imbibing polymers |
US5145874A (en) * | 1985-10-18 | 1992-09-08 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
US5187299A (en) * | 1985-10-18 | 1993-02-16 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
US5196542A (en) * | 1985-10-18 | 1993-03-23 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
WO1987002367A2 (en) * | 1985-10-18 | 1987-04-23 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
US5373095A (en) * | 1985-10-18 | 1994-12-13 | The Upjohn Company | Steroid compounds |
US5274089A (en) * | 1985-10-18 | 1993-12-28 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
US4820714A (en) * | 1986-05-02 | 1989-04-11 | University Of Virginia Alumni Patents Foundation | Use of phospholipase inhibitors in the treatment of Clostridium difficile diarrhea |
US5001234A (en) * | 1987-04-16 | 1991-03-19 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
IL84252A (en) * | 1987-10-23 | 1994-02-27 | Yissum Res Dev Co | Phospholipase inhibiting compositions |
US4948813A (en) * | 1987-11-30 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Benzylketone phospholipase A2 inhibitors |
US5039706A (en) * | 1987-11-30 | 1991-08-13 | Du Pont Merck Pharmaceutical Company | Antiinflammatory PLA2 inhibitors |
US5124334A (en) * | 1987-11-30 | 1992-06-23 | Du Pont Merck Pharmaceutical Company | Benzylalcohol phospholipase A2 inhibitors |
US5218124A (en) * | 1989-10-27 | 1993-06-08 | American Home Products Corporation | Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase |
US5086067A (en) * | 1989-12-18 | 1992-02-04 | G. D. Searle & Co. | Ltb4 synthesis inhibitors |
US5144045A (en) * | 1990-11-13 | 1992-09-01 | American Cyanamid Company | Phosphocholine derivative inhibitors of phospholipase A2 |
US5298652A (en) * | 1992-12-08 | 1994-03-29 | Hoffmann-La Roche Inc. | N-substituted glycines, inhibitors of phospholipase A2 |
HU213165B (en) * | 1993-05-11 | 1997-02-28 | Bot | Process to prepare biopolymers with detoxicating activity |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
GB9324409D0 (en) * | 1993-11-27 | 1994-01-12 | Smithkline Beecham Plc | Novel composition |
RU2128169C1 (ru) * | 1994-04-01 | 1999-03-27 | Эли Лилли Энд Компани | Iн-индол-3-глиоксиламиды, ингибирующие spla2-медиируемое выделение жирных кислот, фармацевтическая композиция |
US5470882A (en) * | 1994-06-02 | 1995-11-28 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
US5504073A (en) * | 1994-07-01 | 1996-04-02 | Warner-Lambert Company | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
US5578639A (en) * | 1994-07-01 | 1996-11-26 | Warner-Lambert Company | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
JPH08268916A (ja) * | 1995-03-28 | 1996-10-15 | Dai Ichi Seiyaku Co Ltd | 微粒子性運搬体−薬物コンプレックス |
JP3372408B2 (ja) * | 1995-09-21 | 2003-02-04 | 第一製薬株式会社 | 微粒子性運搬体・薬物−コンプレックス |
AU3767997A (en) * | 1996-08-01 | 1998-02-25 | Merckle Gmbh | Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2 |
US6630496B1 (en) * | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
CA2264020A1 (en) * | 1996-08-26 | 1998-03-05 | Jean Bemis | Inhibitors of phospholipase enzymes |
US6423754B1 (en) * | 1997-06-18 | 2002-07-23 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with polyallylamine polymers |
US6290947B1 (en) * | 1997-09-19 | 2001-09-18 | Geltex Pharmaceuticals, Inc. | Ionic polymers as toxin-binding agents |
US6350892B1 (en) * | 1997-09-23 | 2002-02-26 | Bristol-Myers Squibb Company | Trifluoromethyl ketone analogs as selective cPLA2 inhibitors |
US6083497A (en) * | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
US6267952B1 (en) * | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
US6264937B1 (en) * | 1998-01-09 | 2001-07-24 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
US6299868B1 (en) * | 1999-07-14 | 2001-10-09 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
TR200002445T2 (tr) * | 1998-02-25 | 2000-12-21 | Genetics Institute, Inc. | Fosfolipaz inhibitörleri. |
US6916841B2 (en) * | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
WO2000010568A1 (en) * | 1998-08-24 | 2000-03-02 | Draheim Susan E | Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase a¿2? |
AR022204A1 (es) * | 1999-01-08 | 2002-09-04 | Norgine Bv | Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende. |
WO2000043036A2 (en) * | 1999-01-22 | 2000-07-27 | Hunza Di Maria Carmela Marazzita S.A.S. | Lipoprotein complexes and compositions containing them |
WO2001051003A2 (en) * | 2000-01-10 | 2001-07-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
US20020001614A1 (en) * | 2000-02-10 | 2002-01-03 | Kent Jorgensen | Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof |
US6492550B2 (en) * | 2000-02-18 | 2002-12-10 | Bristol-Myers Squibb Company | Alpha-substituted thio, -oxo trifluoromethylketones as phospholipase inhibitors |
DE60132256T2 (de) * | 2000-11-20 | 2008-12-24 | Sorbent Therapeutics, Inc., Vernon Hills | Wasserabsorbierende polymere und deren verwendung |
US6368842B1 (en) * | 2000-12-15 | 2002-04-09 | Pe Corporation (Ny) | Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
TWI314457B (ja) * | 2001-03-19 | 2009-09-11 | Shionogi & Co | |
US6495596B1 (en) * | 2001-03-23 | 2002-12-17 | Biozibe Laboratories, Inc. | Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2 |
WO2003048122A2 (en) * | 2001-12-03 | 2003-06-12 | Wyeth | Inhibitors of cytosolic phospholipase a2 |
US20030225011A1 (en) * | 2002-05-31 | 2003-12-04 | Samuel David | Phospholipase A2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease |
US6565896B1 (en) * | 2002-07-03 | 2003-05-20 | Vitacost.Com, Inc. | Cholesterol treatment formulation |
ATE457716T1 (de) * | 2002-12-30 | 2010-03-15 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
-
2004
- 2004-05-03 US US10/838,879 patent/US20050244367A1/en not_active Abandoned
-
2005
- 2005-05-03 WO PCT/US2005/015416 patent/WO2005112646A2/en active Application Filing
- 2005-05-03 EP EP05741781A patent/EP1747003A4/en not_active Withdrawn
- 2005-05-03 US US11/579,251 patent/US20070292385A1/en not_active Abandoned
- 2005-05-03 EP EP05779544A patent/EP1750699A4/en not_active Withdrawn
- 2005-05-03 JP JP2007511528A patent/JP2007536249A/ja active Pending
- 2005-05-03 US US11/579,253 patent/US20080021049A1/en not_active Abandoned
- 2005-05-03 CA CA002565416A patent/CA2565416A1/en not_active Abandoned
- 2005-05-03 CA CA002565448A patent/CA2565448A1/en not_active Abandoned
- 2005-05-03 CA CA002565384A patent/CA2565384A1/en not_active Abandoned
- 2005-05-03 JP JP2007511494A patent/JP2007536243A/ja active Pending
- 2005-05-03 WO PCT/US2005/015281 patent/WO2005112953A2/en active Application Filing
- 2005-05-03 WO PCT/US2005/015418 patent/WO2005107766A1/en active Application Filing
- 2005-05-03 EP EP05779968A patent/EP1750730A4/en not_active Withdrawn
- 2005-05-03 JP JP2007511527A patent/JP2007538009A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007538009A5 (ja) | ||
JP2007536243A5 (ja) | ||
JP6941109B2 (ja) | Fxrアゴニストを使用するための方法 | |
ES2954451T3 (es) | Composiciones y usos de derivados de amidina | |
KR101962209B1 (ko) | 간 질환 치료를 위한 1,3-디페닐프로프-2-엔-1-온 유도체의 용도 | |
RU2328283C2 (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
US9271950B2 (en) | Compositions for treating chronic inflammation and inflammatory diseases | |
BR112015015870B1 (pt) | Uso de uma composição farmacêutica | |
ES2953522T3 (es) | Compuestos de succinato novedosos con permeabilidad celular | |
JP2022020701A (ja) | ベータ-ヒドロキシブチレート及びブタンジオールの中鎖脂肪酸エステル並びに組成物、並びにそれを使用するための方法 | |
ES2958524T3 (es) | Isomiosmina para uso en el tratamiento de enfermedades autoinmunes | |
KR20110011628A (ko) | 세포 스트레스 반응 조절을 통한 알츠하이머 질환 및 관련 장애의 치료를 위한 신규 치료학적 접근법 | |
BRPI0511327A (pt) | combinações de glicopirrolato e agonistas do adrenorreceptor beta2 | |
JP2016128452A (ja) | ナイアシン模倣体、およびその使用方法 | |
BR112015015864B1 (pt) | Uso de uma composição farmacêutica no tratamento de uma condição de dor severa | |
KR20080106455A (ko) | 대사장애의 조합치료 | |
EA028535B1 (ru) | Способы лечения с применением липидных соединений | |
JP2008115167A (ja) | トラネキサム酸を含有する気道杯細胞過形成抑制剤 | |
JP6202633B2 (ja) | ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法 | |
US20130005800A1 (en) | Composition for transdermal or transmucosal administration | |
US20190160057A1 (en) | New treatment for the non alcoholic steatohepatitis and fibrosis | |
JP6153264B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用 | |
JP2007509946A5 (ja) | ||
JP2017039762A (ja) | ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法 | |
US20240130994A1 (en) | Ionic liquid formulations for treating diabetes |